LEGN - Legend Biotech Corp - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US52490G1022
Cell Therapies, Cancer Treatments, Autologous CAR-T Products
Legend Biotech Corporation is a clinical-stage biopharmaceutical company that focuses on the discovery, development, manufacturing, and commercialization of innovative cell therapies for various diseases, including cancer.
The company's lead product candidate, LCAR-B38M, is a chimeric antigen receptor (CAR) designed to treat multiple myeloma, a type of blood cancer. In addition to LCAR-B38M, Legend Biotech has a diverse portfolio of autologous CAR-T product candidates in various stages of development, targeting a range of cancers, including non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and several types of solid tumors such as gastric, esophageal, pancreatic, colorectal, hepatocellular, small cell lung, and non-small cell lung cancers.
Legend Biotech has established a strategic collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ciltacabtagene autoleucel, a CAR-T cell therapy. This partnership enables the company to leverage Janssen's expertise and resources to accelerate the development and commercialization of this promising therapy.
Founded in 2014, Legend Biotech is headquartered in Somerset, New Jersey, and operates as a subsidiary of Genscript Biotech Corporation. The company's commitment to innovation and collaboration has positioned it as a leader in the development of novel cell therapies, with the potential to transform the treatment of various diseases.
For more information, please visit Legend Biotech's website at https://www.legendbiotech.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
LEGN Stock Overview
Market Cap in USD | 7,941m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2020-06-05 |
LEGN Stock Ratings
Growth 5y | 21.0 |
Fundamental | -52.8 |
Dividend | |
Rel. Performance vs Sector | -7.30 |
Analysts | 4.33/5 |
Fair Price Momentum | 37.09 USD |
Fair Price DCF | - |
LEGN Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
LEGN Growth Ratios
Growth Correlation 3m | -82.1% |
Growth Correlation 12m | -66.1% |
Growth Correlation 5y | 74.6% |
CAGR 5y | 4.70% |
CAGR/Mean DD 5y | 0.22 |
Sharpe Ratio 12m | -0.69 |
Alpha vs SP500 12m | -58.41 |
Beta vs SP500 5y weekly | 0.62 |
ValueRay RSI | 41.20 |
Volatility GJR Garch 1y | 44.10% |
Price / SMA 50 | -9.4% |
Price / SMA 200 | -13.38% |
Current Volume | 1051.7k |
Average Volume 20d | 1387k |
External Links for LEGN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 45.30 with a total of 1,051,737 shares traded.
Over the past week, the price has changed by +4.26%, over one month by -8.06%, over three months by -19.65% and over the past year by -31.44%.
According to ValueRays Forecast Model, LEGN Legend Biotech Corp will be worth about 40.6 in October 2025. The stock is currently trading at 45.30. This means that the stock has a potential downside of -10.29%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 83.1 | 83.5 |
Analysts Target Price | 88.4 | 95.1 |
ValueRay Target Price | 40.6 | -10.3 |